LOGOLOGOLOGOLOGO
  • About us
    • What we do
    • Who we are
      • Governance
      • Staff
      • Vacancies
  • Members
    • EuropaBio Members
    • About Membership
  • How we work
    • Healthcare Biotechnology Council
      • Patient BioForum
      • Study – Impact of the EU’s General Pharmaceutical Legislation
    • Industrial Biotechnology Council
      • EFIB
      • Microorganisms
    • National Associations Council
    • SME Platform
    • Biomanufacturing Platform
      • Biotechnology in our Lives
  • Activities
    • 25 Years of Innovation
    • The EU Biotech Act
    • European Biotech Week
    • EU Projects
      • PRIMED Project
      • APROVALS Project
  • News & Events
    • News
    • Events
  • Library
Become a member
✕

Wealth of innovation on display & bio-based winners revealed at EFIB 2019 in Brussels

10/10/2019
PRESS RELEASE

Wealth of innovation on display & bio-based winners revealed at EFIB 2019 in Brussels

The John Sime Award for the best innovation presentation delivered at EFIB 2019 was granted to Guillaume Daoulas, Head of Strategic Marketing at Ÿnsect. In the exhibition, a new area was featuring 20 academic posters. The prize of the best academic poster was awarded to Thomas Gassler from the University of Natural Resources and Life Sciences, Vienna.

Brussels, 10 October 2019 – Industry, science and policy experts met in Brussels for the 12th edition of EFIB on 1-2 October. The event saw a significant international presence, with close to 500 participants from 30 countries and over 260 companies. In focus was how industrial biotechnology and bioeconomy contribute towards establishing a healthy and sustainable planet.

The two days included 13 sessions with over 80 speakers, giving insights on trends, innovation and regulation in food & feed, plastics, bio-based industrial processes, national bioeconomy policies, novel feedstocks, materials and fashion. Also on site were 30 start-ups populating the second edition of the EFIB start-up village.

Recognised by fellow EFIB delegates, this year’s John Sime Award for the best innovation presentation was given to Guillaume Daoulas, Head of Strategic Marketing at Ÿnsect. It is not the first time this French company, an innovator in farming insects and turning them into high-value ingredients for aquaculture, pet nutrition and fertilisers, takes home the coveted award at EFIB. The company has secured significant funding this year to scale up production, including backing from the Horizon2020 BBI programme for the FARMYNG project to build the first fully automated insect-based protein plant.

20 academic posters were also displayed, attracting significant interest. Thomas Gassler from the University of Natural Resources and Life Sciences, Vienna won EFIB’s poster session with their contribution on “CarboFeed: A biotech based platform technology for CO2 utilisation in yeast”.

#EFIB2019 was also home to other announcements and saw Michelin presenting for the first time officially its new €28 million BioImpulse project, aiming to create a new adhesive resin without any of the so-called ´Substances of Very High Concern´. Presenting on the economic potential of the bioeconomy, opening plenary speaker María Mendiluce, Managing Director for Climate & Energy, Cities & Mobility and Circular Economy at the World Business Council for Sustainable Development (WBCSD) also informed about the forthcoming publication of a “CEO guide to the Bioeconomy” to help companies setting up an appropriate strategy in this field.

Agnes Borg, Industrial Biotech Director, EuropaBio commented: “EFIB aims to provide a central place for policy, business communities and other stakeholders to meet, exchange and collaborate. It remains a key forum highlighting achievements and potential of the circular bioeconomy, enabled by industrial biotechnology. We are delighted to congratulate this year´s award winners, and also extend our sincere thanks to all who contributed to this year´s event”.

The 2020 EFIB will be held on 5-6 October 2020 in Frankfurt/Main, Germany.

Wealth of innovation on display & bio-based winners revealed at EFIB 2019 in Brussels


Download
Share
Alexandra Simionca
Alexandra Simionca

Related posts

22/05/2025

Adisseo joins EuropaBio: Feeding Animals Sustainably Around the World


Read more
21/05/2025

Ensuring Biotech Integration in the Single Market


Read more
10/04/2025

EU biotechnology competitiveness for the future; high level dialogue with EVP Séjourné


Read more

Important links

  • Adisseo joins EuropaBio: Feeding Animals Sustainably Around the World
  • Ensuring Biotech Integration in the Single Market

Categories in our Newsroom

EBIO-white

EuropaBio represents corporate and associate members across sectors, plus national and regional biotechnology associations which, in turn, represent over 5000 biotech companies, 4600 out of them are SMEs.

Contact us

Extra links

Members
Staff
Privacy policy
Legal & cookies
Events
Newsroom

Become a member

Media pack

© 2025 Europabio. All Rights Reserved. Designed by EYAS
Become a member

Algal Omega 3

Algal Omega-3 is an innovative feed product for aquaculture. It reduces the impact on climate change by 30-40% compared to fish oil and saves 60 tons of wild fish for every ton of Algal Omega-3 used.

Cheese

Cheese is a vegetarian product thanks to biotechnology. Biotechnology is also essential to produce lactose- or cholesterol-free cheese, as well as alternative proteins.

Clothes

Clothes made from alternative fibres produced by microorganisms can be 8x stronger than steel, 100% recyclable, biodegradable and replace fossil-fuel based or resource-intensive textiles.

Vitamin B2

The biomanufacturing of Vitamin B2 led to the reduction of 75% of fossil raw materials and 50% operating costs, compared to the chemical process. Vitamin B2 is used in the food, feed or healthcare sectors.

Detergents

Enzymes and biosurfactancts are alternative ingredients that improve the performance of detergents, while leading to water and energy savings and reductions in CO2 emissions and water toxicity.

Insulin

Insulin is one of the most widely known biopharmaceutical. Biotechnology revolutionised its manufacturing process and led to the development of new types of insulin through r-DNA technology.